Analyst Price Target is $3.00
▲ +384.18% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vaxart in the last 3 months. The average price target is $3.00, with a high forecast of $4.00 and a low forecast of $2.00. The average price target represents a 384.18% upside from the last price of $0.62.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Vaxart. This rating has held steady since November 2023, when it changed from a Moderate Buy consensus rating.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Read More
